The rationale of testing the ability of tezosentan, a dual ET-1 receptor antagonist, to prevent BHR emerged from the crucial involvement of ET-1 in the pathogenesis of PHT [25]. The gene discussed is EDN1; the disease is pulmonary hypertension, primary, 1.